Xeris Biopharma Holdings Inc

Insider trading shows Xeris Biopharma’s leadership remains bullish, with Nguyen Anh Tu’s recent sell‑off a tactical move, not a loss of confidence, as the company pushes its injectables platform toward launch.

Insightful insider sale of Xeris Biopharma shares shows cautious liquidity strategy amid recent revenue beat, urging investors to watch upcoming clinical milestones for true upside.

Kevin McCulloch’s 15,000‑share sale at Xeris Biopharma is a routine 10b‑5 plan liquidity move, not a signal of weakness amid strong revenue outlook and 14.27% monthly gains.